- Home
- RGC vs AGEN Comparison
RGC vs AGEN Comparison
Compare RGC & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- AGEN
- Stock Information
- Founded
- RGC 2014
- AGEN 1994
- Country
- RGC Hong Kong
- AGEN United States
- Employees
- RGC N/A
- AGEN N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RGC Health Care
- AGEN Health Care
- Exchange
- RGC Nasdaq
- AGEN Nasdaq
- Market Cap
- RGC 105.3M
- AGEN 96.2M
- IPO Year
- RGC 2021
- AGEN 2000
- Fundamental
- Price
- RGC $6.13
- AGEN $2.72
- Analyst Decision
- RGC
- AGEN Buy
- Analyst Count
- RGC 0
- AGEN 3
- Target Price
- RGC N/A
- AGEN $9.33
- AVG Volume (30 Days)
- RGC 221.5K
- AGEN 516.0K
- Earning Date
- RGC 11-29-2024
- AGEN 11-12-2024
- Dividend Yield
- RGC N/A
- AGEN N/A
- EPS Growth
- RGC N/A
- AGEN N/A
- EPS
- RGC N/A
- AGEN N/A
- Revenue
- RGC N/A
- AGEN $160,427,000.00
- Revenue This Year
- RGC N/A
- AGEN N/A
- Revenue Next Year
- RGC N/A
- AGEN $0.04
- P/E Ratio
- RGC N/A
- AGEN N/A
- Revenue Growth
- RGC N/A
- AGEN 59.00
- 52 Week Low
- RGC $3.03
- AGEN $2.58
- 52 Week High
- RGC $32.44
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- RGC 48.30
- AGEN 17.93
- Support Level
- RGC $6.08
- AGEN $2.98
- Resistance Level
- RGC $6.71
- AGEN $4.42
- Average True Range (ATR)
- RGC 1.34
- AGEN 0.28
- MACD
- RGC -0.10
- AGEN -0.13
- Stochastic Oscillator
- RGC 12.59
- AGEN 7.17
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).